Novo Nordisk’s Fiasp shows strong blood sugar control in under-18 type 1 diabetes patients
pharmafile | October 12, 2018 | News story | Medical Communications, Research and Development | Fiasp, Novo Nordisk, Type 1 diabetes, diabetes, pharma
New data unveiled by Novo Nordisk has shown that its insulin injection Fiasp (fast-acting insulin aspart) could provide a better option for child and adolescent patients with type 1 diabetes to manage their blood sugar levels compared to existing therapies when administered multiple times a day.
The data, presented at the 44th Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), demonstrated that patients using Fiasp at mealtimes saw “superior reductions in overall blood sugar levels (HbA1c)”, compared to conventional insulin aspart. Additionally, they also achieved significantly lower overall post-meal blood sugar levels one hour after meals.
Patients who injected Fiasp 20 minutes after beginning a meal also saw similarly strong results, supporting the drug’s non-inferiority.
“Fiasp has already helped to reduce challenges around mealtime blood sugar control for adults with diabetes, and it is exciting to see that similar benefits are achieved with children and adolescents in this trial,” said lead researcher Dr Bruce Bode, Diabetes Specialist with Atlanta Diabetes Associates in Atlanta. “These findings show that Fiasp may offer a suitable option to improve blood sugar control and better meet the needs of this specific population.”
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, also remarked: “It can be hard for the parents and caregivers of children with type 1 diabetes to know exactly how much or how fast their children will eat, making the dosing of mealtime insulin challenging in relation to both timing and quantity. These results show that Fiasp may be able to ease some of the burden of diabetes management at mealtimes for children and adolescents, as well as those who care for them. We hope to make this ultra-fast treatment option available to benefit this population as soon possible.”
Matt Fellows
Related Content
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche shares data on novel solution for continuous glucose monitoring
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …
